Abstract
Peroxisome proliferator-activated receptor alpha (PPAR??) regulates transcription of genes involved both in lipid and glucose metabolism as well as in inflammation. Fibrates are PPARα ligands used to normalize lipid and glucose parameters and exert antiinflammatory effects. In fact, fibrates have already been demonstrated to benefit metabolic syndrome, type 2 diabetes and cardiovascular diseases. This article reviews the mechanism of action and the functional roles of fibrates, emphasizing the factors modulating their capacity to activate PPARα and affecting their effectiveness. These factors may possibly explain the findings obtained in animal studies and clinical trials with fibrates which showed either untoward effects and/or inefficient hypolipidemic action of PPARα activation. We also discuss briefly the natural and synthetic agonists of PPARαwhich are currently being developed and supposedly display greater effectiveness and fewer adverse effects than fibrates.
Keywords: Peroxisome proliferator-activated receptor, fibrates, natural PPAR agonists, synthetic PPAR activators, metabolic syndrome, type 2 diabetes, cardiovascular disease
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Volume: 9 Issue: 3
Author(s): M. I. Panadero, M. C. Gonzalez, E. Herrera and C. Bocos
Affiliation:
Keywords: Peroxisome proliferator-activated receptor, fibrates, natural PPAR agonists, synthetic PPAR activators, metabolic syndrome, type 2 diabetes, cardiovascular disease
Abstract: Peroxisome proliferator-activated receptor alpha (PPAR??) regulates transcription of genes involved both in lipid and glucose metabolism as well as in inflammation. Fibrates are PPARα ligands used to normalize lipid and glucose parameters and exert antiinflammatory effects. In fact, fibrates have already been demonstrated to benefit metabolic syndrome, type 2 diabetes and cardiovascular diseases. This article reviews the mechanism of action and the functional roles of fibrates, emphasizing the factors modulating their capacity to activate PPARα and affecting their effectiveness. These factors may possibly explain the findings obtained in animal studies and clinical trials with fibrates which showed either untoward effects and/or inefficient hypolipidemic action of PPARα activation. We also discuss briefly the natural and synthetic agonists of PPARαwhich are currently being developed and supposedly display greater effectiveness and fewer adverse effects than fibrates.
Export Options
About this article
Cite this article as:
Panadero I. M., Gonzalez C. M., Herrera E. and Bocos C., Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/187153009789044356
DOI https://dx.doi.org/10.2174/187153009789044356 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
Current Cancer Therapy Reviews The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Tracking the Mesenchymal Stem Cell Fate After Transplantation Into the Infarcted Myocardium
Current Stem Cell Research & Therapy Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Current Pharmaceutical Design Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]
Current Pharmaceutical Design Patent Selections
Recent Patents on Medical Imaging Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology The Role of Fibrate Treatment in Dyslipidemia: An Overview
Current Pharmaceutical Design Valosin Containing Protein Associated Fronto-Temporal Lobar Degeneration:Clinical Presentation, Pathologic Features and Pathogenesis
Current Alzheimer Research Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Cardiovascular Risk Factors, Metabolic Complications, & the Natural Course of CKD in Children
Current Hypertension Reviews Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?
Current Pharmaceutical Design The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets (Discontinued)